Scientists are reevaluating the causes of Alzheimer's beyond the amyloid hypothesis after numerous experimental drugs designed to target that theory have failed.

Recent evidence raises the question of whether conventional wisdom about amyloid plaques and their connection to Alzheimer's is wrong.

"Plaques" and "tangles" are top potential causes of Alzheimer's—but questions remain

The exact causes of Alzheimer's—and how to treat it—continue to be the subject of intense research. Two leading factors are amyloid beta plaques and tau protein tangles, which effectively pile up in the brain and interfere with neurons and cause cell death, which manifests as memory loss and other symptoms.

More than 200 drug trials for Alzheimer's have failed or been abandoned since 2010, but two anti-amyloid infusion medications have netted FDA approval in recent years.

Explore this 1440 Original video offering a primer on Alzheimer's disease and what's known about its incidence, causes, and more.

Early-onset Alzheimer's can appear as early as age 30, but estimates of its prevalence remain uncertain.

Alzheimer's can cause significant brain shrinkage in the affected brain regions, including the hippocampus.

Visualize the difference between a healthy brain and one with Alzheimer's.

Alzheimer's brain changes may begin years before symptoms appear.

There are two FDA-approved blood tests that may detect early Alzheimer's disease.

Alzheimer's disease is the leading cause of dementia and risks rise after age 65

Read this primer about Alzheimer's disease and learn what factors increase the risk of this form of dementia, including genetics, being a woman, and health conditions, including high blood pressure.

A top Alzheimer's researcher was accused of faking results

In 2021, an investigation revealed photo manipulation in images from a seminal 2006 paper by researcher Sylvain Lesné on the role of amyloid plaques in progressive Alzheimer's disease. The revelation rocked the field, leaving many wondering whether they had tried to build on fabricated results. (Some users may experience a paywall.)

How Alzheimer's disease becomes fatal

Despite more than 100,000 people with Alzheimer's dying each year, the specific cause of death is not the disease itself. Often, secondary diseases arise from complications with the disease, including pneumonia, severe falls, malnutrition, or infection. Read more about the range of complications caused by Alzheimer's here.

Poor sleep increases the risk of developing Alzheimer's, and a main reason appears to be that the brain disposes of toxic protein buildup during high-quality sleep.

Multiple genes are associated with Alzheimer's risk, but one particularly well-known disease-associated gene is apolipoprotein E (APOE), which typically encodes a protein that helps carry cholesterol and other fats in the bloodstream.

Researchers are exploring neural links between Alzheimer's and autism

Recent DNA sequencing and molecular biology studies suggest that similarities in genes, neural circuitry and patterns of disease warrant further exploration to potentially better understand both conditions and how to treat them. (Some users may encounter a paywall.)

Medical experts warn that completing genetic testing for Alzheimer's can be fraught, in part because there's a shortage of genetic counselors to help navigate the findings and their potential implications.

Chronic drug use can cause neurological changes in the brain

Neuroscientist Judy Grisel breaks down the biology of addiction, examining how drugs hijack the brain’s natural reward system and create lasting neural changes. The physiological and neurological impacts of chronic drug use require a multifaceted treatment approach.

Some dementia cases may be linked to treatable microorganism infections in the brain.

Genetic blood test offers an estimated clock on when Alzheimer's symptoms may appear

The 2026 research finding from researchers at Washington University School of Medicine in St. Louis—if validated in broader populations—suggests that an already available blood test could estimate when Alzheimer's symptoms may begin within a margin of several years. The test detects a protein called p-tau217 found in blood plasma and the researchers incorporated the findings from that blood test into a statistical model to come up with the symptom timeline predictions.

Does our fear of Alzheimer's create stigma around its treatment?

Surveys suggest our fear of Alzheimer's as a disease outranks that of heart disease and cancer. This piece argues our fear of aging and the slipping away of our mental capacities make it more difficult to treat Alzheimer's compassionately.

Five to ten percent of Alzheimer's cases are early-onset

Early-onset Alzheimer’s typically emerges around 40 to 50 years of age, with devastating effects. This video follows Brian, diagnosed with the disease at age 54, as he travels the country as an advocate for research and discusses the progressive mental fog of Alzheimer’s.

Alzheimer's in the United States is most prevalent in the South and the East.

The first identification of Alzheimer's was made in 1906.

How ALS (Lou Gehrig's Disease) might work, and what scientists are learning about it

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder that affects the nerve cells (neurons) controlling muscle movement. As the motor neurons degenerate, they stop sending signals to the muscles, causing progressive muscle weakness and, eventually, death. This three-minute animation focuses on the mechanisms within the motor neurons that cause them to degenerate. By understanding these mechanisms, researchers hope to one day find a cure for ALS.

How depression affects the brain

Treatment for depression has historically hinged on the theory that the condition was caused by underactive or abnormal neurotransmitters, specifically serotonin and norepinephrine. This four-minute video by Yale Medicine details how these neurotransmitters didn't explain the symptoms of depression but, two other neurotransmitters involved in regulating mood and emotion did. GABA and glutamate, some of the brain's most plentiful neurotransmitters, may possibly be the source of depressive symptoms.

Neurodegeneration is the process underlying dementia, but it may happen for myriad reasons, and its triggers are under investigation.

MS Drugs reduce inflammation, helping reduce relapses and slow disease progression

Disease-Modifying Drugs calm the body's inflammatory response to help stave off relapses—when new or existing MS symptoms show up for a day or longer. Avoiding smoking, exercising, reducing stress via mindfulness, checking for vitamin D deficiencies, drinking more water and eating well, all can slow disease progression. [The jury's still out on if HRT around the time of menopause may reduce dementia risk](https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(25)00122-9/fulltext) Estrogen can reduce inflammation and support neural growth in the brain, and some research has suggested that beginning hormone replacement therapy around menopause—versus later in life—reduces Alzheimer's disease risk. Still, a recent systematic review concluded that taking HRT didn't affect dementia risk, regardless of when women started taking it, so the science remains unsettled.

These areas of the brain are hard-hit in depression—but the changes are reversible

Depressed brains can have certain characteristic changes, including an overactive amygdala, reduced hippocampus size, and changes to the thalamus and neuromodulating chemicals in the brain.

How aging degrades neural functioning in the brain over time

Aging affects the brain perhaps more than any other organ in the body. Throughout life, the brain experiences radical shifts in the number of neurons, synaptic connections between neurons, and hormone levels that regulate our mood and processing.

Researchers use the brain's ability to edit memories to explore memory deletion

Scientists have successfully implanted false memories in mice after studying how the editing process works in the brain. Beyond potentially deleting memories in those with PTSD, upcoming research may allow clinicians to forecast the onset of neurodegenerative diseases.

Memory disorders disrupt the brain's ability to make, store, or recall memories

These disorders stem from reversible issues like vitamin deficiencies or irreversible causes such as stroke or dementia. Only one type of dementia—familial Alzheimer’s disease—is directly inherited and accounts for about 20% of Alzheimer’s cases.

Depression changes the brain, causing distinct structural alterations visible on brain scans, but effective treatment can eventually make a depressed brain resemble a healthy one.

Read the original 1907 paper on the first known Alzheimer's patient, which was identified by Dr. Alois Alzheimer.

Age, stress, and neurological disorders can prevent memory formation and recall

Neurons transmit signals between one another at sites called synapses. Repeated interactions at these sites improve the efficiency of signal transmissions, making memories involving sensory data associated with those neurons easier to recall. Biochemical factors impacting these synaptic interactions affect memory quality.

Minorities are largely underrepresented in medical research, which compromises our understanding of how conditions and treatments may affect various populations, but recent efforts, like the African Ancestry Neuroscience Research Initiative and new genome research studies, are seeking to close that gap.

See how antidepressants—used by roughly 1 in 10 Americans—were discovered.

An Alzheimer's patient discusses her condition with children

Alzheimer's is a deadly disease that profoundly changes a person's abilities and personality, which makes it difficult to explain to kids. Responding to potentially uncomfortable questions with honesty (and relatable imagery) about the costs and nature of the disease goes a long way in fostering understanding.

Resistance training is linked to better memory and cognitive function in older adults.

Retired professional soccer players are showing signs of potential neurological impacts in midlife, according to a study presented at the July 2026 Alzheimer's Association International Conference in London.

Schizophrenia is being studied with pea-sized 'mini-brains'

Brain organoid research is enabling researchers to study distinct electrical firing patterns associated with schizophrenia. These "mini-brains" that are constructed in the lab from patients' cells could lead to better diagnosis approaches and drug development.

An analysis of ancient texts found that dementia was rare in ancient Greece.

Remylination is a huge focus for treatment—especially among older adults

Our ability to build new myelin sheaths for nerves degrades with age. There have been research advances boosting cells that support these processes and clear away debris from degraded myelin, but not yet any medications to boost myelination itself, which would aid nerve signaling and preserve nerve function.

The disease no one survives (yet)

Creutzfeldt-Jakob disease is currently incurable and can cause one's death within months of symptoms appearing. It involves misfolded proteins that, for some reason yet unknown to science, aren't cleared by the brain as typical and instead trigger similar proteins to misfold. These malformed major prion proteins—prion being a portmanteau of protein and infection—clump inside nerve cells, blocking signals crucial to processes ranging from speaking to organ function.

Why vascular dementia develops

This type of dementia, the second most common form after Alzheimer's, develops due to microscopic bleeds and blood vessel blockages in the brain. The condition isn't curable but medications to help with blood clotting and high blood pressure are part of a suite of interventions designed to minimize damage to the brain.

Addictive drugs can cause dopamine levels to become ten times higher than normal.

Face and neck massages improve the removal of brain cell waste products in mice

A study identified that massaging mice and monkeys' faces and necks enhanced the flow of cerebrospinal fluid. Because CSF has been shown to flush out proteins linked to Alzheimer's and Parkinson's, the research hints at non-invasive treatments to reduce the severity of these diseases.

US FDA recently approved the first new schizophrenia drug in decades

Though other antipsychotics block dopamine receptors, a new drug, Cobenfy, influences dopamine levels via a different pathway—it stimulates a pair of specialized receptors in the brain that control the release of a substance called acetylcholine. This alternative approach may help patients avoid serious side effects like weight gain. (Some users may experience a paywall.)

Rodent evidence is mounting that dysfunctional mitochondria may be a cause of Parkinson's

Though researchers have long observed mitochondrial malfunction in Parkinson's patients, it has remained unclear whether faulty mitochondria cause the disease or are casualties of it. Rodent research published in 2025 adds further weight to the idea that it's causative.

Long-term memory formation may not need short-term memory

New research shows that long-term memories can still develop even when short-term memory formation is blocked, suggesting the brain uses separate pathways for short- and long-term memory. This discovery could help scientists open new avenues for treating memory loss in diseases like Alzheimer’s.

Advanced drugs are closing in on cancer's deadliest mutations

The protein KRAS, mutated in many cancers, was deemed ‘undruggable’. Now scientists are hoping to save lives with a batch of new compounds that target it.